Vol 65, No 4 (2015)
Invited editorial
Published online: 2015-09-11

open access

Page views 834
Article views/downloads 2704
Get Citation

Connect on Social Media

Connect on Social Media

Prophylaxis and treatment of venous thromboembolism in medical cancer patients

Jerzy Windyga
DOI: 10.5603/NJO.2015.0054
Nowotwory. Journal of Oncology 2015;65(4):257-265.


Malignancy is one of the major independent risk factors for the development of venous thromboembolism (VTE) that involves deep vein thrombosis (DVT) and pulmonary embolism (PE). Epidemiological data indicate that 20% of all VTE cases occur in cancer patients. Moreover, VTE is reported in up to every fifth patient with malignant neoplasm and is the second (after neoplasm itself ) leading cause of death in this group of patients. The aim of this paper is to present the principles of prophylaxis and treatment of venous thromboembolism in medical patients with cancer, either being treated in outpatient or inpatient setting. The paper will also address management of challenging cases, such as recurrent VTE or VTE in a patient with thrombocytopenia, active bleeding or renal insufficiency.

Nowotwory. Journal of Oncology